29682-15-3

Basic information

• Product Name: 5-BROMOPYRIDINE-2-CARBOXYLIC ACID METHYL ESTER
• Synonyms: Methyl 5-bromopyridine-2-carboxylate, 98+%;5-broMopicolinic acid Methyl ester;5-BROMOPYRIDINE-2-CARBOXYLIC ACID METHYL ESTE;Methyl 5-bromopicolinate, 5-Bromo-2-(methoxycarbonyl)pyridine;Methyl 5-BroMopyridine-2-carboxylate, 97+%;5-bromopyridin-2-carboxylic acid methyl ester;METHYL 5-BROMO-2-PYRIDINECARBOXYLATE;METHYL 5-BROMOPICOLINATE
• CAS NO: 29682-15-3
• Molecular Formula: C₇H₆BrNO₂
• Molecular Weight: 216.03
• EINECS: -0
• Product Categories: Pyridines;Pyridine;Pyridine Series;Boronic Acid;Quinolines;blocks;Bromides;Carboxes
• Mol File: 29682-15-3.mol
• Article Data: 29

Chemical Properties

• Melting Point: 101-103°C
• Boiling Point: 290.9 °C at 760 mmHg
• Flash Point: 129.7 °C
• Appearance: /
• Density: 1.579 g/cm³
• Vapor Pressure: 0.00202mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.67±0.10(Predicted)
• Water Solubility: Soluble in water.
• CAS DataBase Reference: 5-BROMOPYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOPYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(29682-15-3)
• EPA Substance Registry System: 5-BROMOPYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(29682-15-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 26-37
• Hazardous Substances Data: 29682-15-3(Hazardous Substances Data)

Usage

Uses

Methyl 5-bromopyridine-2-carboxylate is used as an organic chemical synthesis intermediate.

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)6-3-2-5(8)4-9-6/h2-4H,1H3

Upstream product

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 30766-11-1 5-bromoisonicotinic acid 
• 75-77-4 chloro-trimethyl-silane 
• 624-28-2 2,5-dibromopyridine 
• 107-31-3 Methyl formate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 186581-53-3 diazomethane 
• 137178-88-2 5-bromopyridine-2-carbonyl chloride 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 223463-13-6 2-iodo-5-bromopyridine 

Downstream Products

• 959741-32-3 5-bromo-2-(methoxycarbonyl)-1^A[5]-pyridin-1-olate 
• 1033721-77-5 4,5-bis{2-[6-(methoxycarbonyl)pyrid-3-yl]ethynyl}veratrole 
• 77199-09-8 5-bromo-pyridine-2-carboxylic acid ethyl ester 
• 1363374-48-4 C₁₇H₁₂N₂O₂ 
• 1613298-71-7 benzyl 4-(2-amino-2-oxo-ethyl)-4-[[5-cyclopropyl-6-(cyclopropylmethoxy)pyridine-2-carbonyl]amino]piperidine-1-carboxylate 
• 1613297-28-1 {3-[(5-cyclopropyl-6-cyclopropylmethoxy-pyridine-2-carbonyl)-amino]-oxetan-3-yl}-acetic acid ethyl ester 
• 1459772-62-3 3-pyridyl-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]methanol 
• 1459772-66-7 (5-bromopyridin-2-yl)(pyridin-3-yl)methanol 
• 1459768-38-7 1-ethyl-3-[6-fluoro-5-[6-[hydroxy(3-pyridyl)methyl]-3-pyridyl]-1,3-benzothiazol-2-yl]urea 
• 1380672-73-0 3-(4-(2-chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4H-1,2,4-triazol-3-yl)acrylic acid 
• 1431470-40-4 3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-carboxylic acid methyl ester 
• 1431470-17-5 5-(3-isopropylphenyl)pyridine-2-carboxylic acid 
• 1431469-52-1 3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-carboxylic acid benzylhydroxyamide 
• 1273016-15-1 3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-carboxylic acid 

Relevant articles and documents

SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION

The present invention relates to compounds of formula I: in which A1-A7 and R1 to R5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A1 to A3 is N or at least one of A4 is CR12 or A5 is CR13 in which R12/R13 is halogen.

HETEROCYCLIC INTEGRIN AGONISTS

The present invention provides polycyclic oxothioxoimidazolidines, dioxoimidazolines, oxothioxooxazolidines, dioxooxazolidines, and related compounds, which are useful as integrin agonists. Methods for the treatment of integrin-mediated diseases such as cancer are also described.

Structure–Activity Relationship of Propargylamine-Based HDAC Inhibitors

As histone deacetylases (HDACs) play an important role in the treatment of cancer, their selective inhibition has been the subject of various studies. These continuous investigations have given rise to a large collection of pan- and selective HDAC inhibitors, containing diverse US Food and Drug Administration (FDA)-approved representatives. In previous studies, a class of alkyne-based HDAC inhibitors was presented. We modified this scaffold in two previously neglected regions and compared their cytotoxicity and affinity toward HDAC1, HDAC6, and HDAC8. We were able to show that R-configured propargylamines contribute to increased selectivity for HDAC6. Docking studies on available HDAC crystal structures were carried out to rationalize the observed selectivity of the compounds. Substitution of the aromatic portion by a thiophene derivative results in high affinity and low cytotoxicity, indicating an improved drug tolerance.